p16INK4a-deficient mouse developed more epicardial AT in response to the adipogenic PPARγ agonist rosiglitazone, providing a potential mechanistic link between the genetic association of the INK4a/ARF locus and cardiovascular disease risk [34,35]. This evidence concerns the gene CDKN2A and cardiovascular disorder.